Home > Healthcare > Pharmaceuticals > Finished Drug Form > Muscle Relaxant Drugs Market

Muscle Relaxant Drugs Market Share

Report ID: GMI6559
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Muscle relaxant drugs Market Share

The prominent players in the muscle relaxant drugs market are

Amneal Pharmaceuticals LLC
Ipsen Biopharmaceuticals, Inc
Merz Pharmaceuticals, LLC
Mylan (Viatris)
Sanofi
Pfizer Inc
Novartis AG
eva Pharmaceuticals Industries Ltd, Inc
Vertical Pharmaceuticals
Sun Pharmaceutical Industries Ltd
SteriMax Inc
Par Pharmaceutical
Abbott Laboratories
F. Hoffmann-La Roche AG

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global muscle relaxant drugs industry size was USD 4.1 billion in 2022 and will reach USD 9.4 billion by 2032 with a CAGR of 6.4% from 2023 to 2032.

The muscle spasm & pain relief segment is expected to reach USD 4 billion by end of 2032 owing to the widespread need for efficient solutions to manage muscle-related discomfort.

North America muscle relaxant drugs market held 37.6% revenue share in 2022 and is anticipated to show considerable growth during 2023-2032 attributed to the growing aging population, sedentary lifestyles, and occupational stress.

Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals, Inc, Merz Pharmaceuticals, LLC, Mylan (Viatris), Sanofi, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Industries Ltd, Vertical Pharmaceuticals, Sun Pharmaceutical Industries Ltd, SteriMax Inc, Par Pharmaceutical, Abbott Laboratories and F. Hoffmann-La Roche AG.